糖心视频

launched out of stealth Thursday and is poised to commercialize a new method for the treatment of rheumatoid arthritis. It raised $16.5 million in funding, led by , 1 to continue its clinical trials.

Subscribe to the Crunchbase Daily

The neuroscience startup was co-founded in 2017 by , who previously founded and led (NYSE: NVRO), a company developing pain treatments. 狈脓蝉辞蝉 is creating a wearable earbud and software component that provides a noninvasive, drug-free approach to disease treatment through electric field immunotherapy, dubbed 鈥渆-mmunotherapy.鈥�

鈥淭he brain tries to modulate the immune response,鈥� Alataris told Crunchbase News. 鈥淎t the core is the overactive immune response, in this case inflammation. The central processing is in the brain. We are proving we can actually reach the area of the brain to modify the pathway without deep brain surgery.鈥�

Like other autoimmune disorders, rheumatoid arthritis is rooted in chronic inflammation. Existing treatments, often pharmaceuticals, have adverse side effects, including a decreased immunity, he added. 狈脓蝉辞蝉鈥檚 earbud uses the brain鈥檚 electrical language to provide a new treatment option without pharmaceutical side effects.

The new funding includes an earlier seed round and will be used mainly for continued clinical trials, Alataris said. The San Francisco-based company recently completed a 30-patient clinical trial where data showed a meaningful reduction in RA disease severity.

鈥淲e are running three clinical studies in three indications, one of them rheumatoid arthritis, and we are doing more research to understand the mechanism and to see the exact impact on the brain and electrical fields,鈥� Alataris added. 鈥淚f we continue to get the same promising data, it will be very exciting.鈥�

In addition to continuing with its trials for RA, 狈脓蝉辞蝉 is researching an earbud with neurological and psychiatry capabilities. It plans to seek approval as a medical device.

, Mayfield partner and 狈脓蝉辞蝉 board member, said in an interview that research shows the brain is a unique organ, forming new connections all of the time. While looking around to see where the successes were in the field, he met Alataris.

鈥淭he next generation of neurotherapy is emerging,鈥� Parikh said. 鈥淲e have working on , as well as and in , same as 狈脓蝉辞蝉. However, Google鈥檚 devices require surgery to implant them. Nesos is positioned, based on clinical data, in the next five years to treat hundreds of millions of patients.鈥�

Feature and blogroll photo courtesy of Nesos